BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2006-07, Vol.20 (7), p.1313-1315
Hauptverfasser:	Abe, M, Kido, S, Hiasa, M, Nakano, A, Oda, A, Amou, H, Matsumoto, T
Format:	Artikel
Sprache:	eng
Schlagworte:	APRIL protein B-Cell Activating Factor - physiology Biological and medical sciences Biomedical materials BLyS protein Cancer Research Cell Survival - physiology Critical Care Medicine Hematologic and hematopoietic diseases Hematology Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulin Fc Fragments - genetics Immunoglobulin Fc Fragments - therapeutic use Immunoglobulinopathies Immunopathology Intensive Internal Medicine letter-to-the-editor Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Oncology Osteoclasts - physiology Transmembrane Activator and CAML Interactor Protein - genetics Transmembrane Activator and CAML Interactor Protein - therapeutic use Tumor Necrosis Factor Ligand Superfamily Member 13 - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!